Shimasaki, Craig, PhD, MBA

Dr. Shimasaki received his BS in Biochemistry from the University of California at Davis, his PhD in Molecular Biology and Biotechnology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma and is the co-founder and CEO of Moleculera Biosciences, a neuroimmunology precision medicine company focused on identifying and treating the underlying roots of neurologic, psychiatric, and behavioral disorders triggered by an autoimmune response. He has spent over 35 years working in the fields of molecular biology, viral pathogenesis, and infection-triggered autoimmune neuropsychiatric disorders. Dr. Shimasaki started his career at Genentech and has worked across all stages of research, development, clinical trials, and regulatory approval of technology innovation from bench-to-bedside. His research work includes epitope mapping of HIV proteins, genetic-based predictors of breast cancer risk, influenza and RSV diagnostics and therapeutics, and the pathogenesis of infection-triggered neuropsychiatric disorders. He has co-founded multiple companies and led multiple products through the FDA approval process and is a co-inventor on multiple patents. Internationally, he teaches and mentors scientists, physicians and biotech leaders on how to translate their research into acutely needed medical interventions. His passion is to translate scientific discoveries into acutely needed products so that more patients can live longer, healthier lives.

• Autoimmune Brain Panel (formerly known as the Cunningham Panel): Blood testing in a clinical laboratory for immune-mediated neuropsychiatric disorders, identification of autoimmune antibodies directed against brain targets, and neuronal cell stimulatory assays.

Type of Clients: Both

Take Healthcare Insurance: Yes

• Suspicion of immune-mediated neuropsychiatric disorders that don't respond to traditional psychotropic drugs, such as PANDAS/PANS, portions of schizophrenia, post-treatment Lyme disease, and others.

We are a high complexity, CLIA/COLA accredited clinical laboratory and biotechnology company, performing research and clinical testing for immune-mediated neuropsychiatric disorders.